The Medicines Patent Pool signed sublicences with new generic manufacturing partners Anhui Biochem United Pharmaceuticals from China, as well as Dr. Reddy’s Laboratories and Macleods Pharmaceuticals from India. The three companies have the rights to develop generic versions of ViiV Healthcare’s dolutegravir (DTG) and Gilead Sciences’ portfolio of six products. Dr. Reddy’s Laboratories also signed a licence to manufacture AbbVie’s lopinavir, ritonavir for Africa.
The foundation’s current partners Sun Pharma and Zheijang Huahai signed sublicensing agreements to produce DTG, while Natco was recently granted a sublicence for Gilead Sciences’ products. The MPP is now working with 20 sublicensing partners to produce World Health Organization-recommended and new HIV, hepatitis C and tuberculosis treatments.